Bristol Myers Squibb today announced new four-year results from the extension of a trial of Sotyktu (deucravacitinib) in adult patients with moderate-to-severe plaque psoriasis.

''The data [...] continue to reinforce the potential of Sotyktuen as a standard of oral care for people living with moderate-to-severe plaque psoriasis,'' said Alyssa Johnsen, MD, PhD, senior vice president and head of clinical development, immunology, cardiovascular disease and neuroscience, Bristol Myers Squibb.

After four years of continuous treatment, responses at week 208 for the Psoriasis Area and Severity Index (PASI) 75 and 90 were 71.7% and 47.5%, respectively, and 57.2% for the Static Physician Global Assessment (sPGA) 0/1 (clear/almost clear), the company said.


Copyright (c) 2024 CercleFinance.com. All rights reserved.